Home >> News >> Enterprise Information Encyclopedia

Enterprise Information Encyclopedia

10
/
2026
08

Baiyunshan Hanfang showcased its core product portfolio at the 94th China International API, Intermediates & Packaging Equipment Fair.

From May 13 to 15, 2026, the 92nd National Pharmaceutical Fair (PHARMCHINA) and the 94th China International API / Intermediate / Packaging / Equipment Fair (API China) will grandly open at the National Exhibition and Convention Center (Shanghai). Guangzhou Pharmaceutical Group will make a major appearance with its core product portfolio, building on the momentum of the previous Suzhou investment promotion conference. Driven by its “Four Modernizations” strategy, the group will showcase its innovative achievements across the entire industrial chain and its international cooperation initiatives, thereby contributing to the high-quality development of China’s pharmaceutical industry.

06
/
2026
08

Guangzhou Baiyunshan Hanfang Launches MCT for Fat Emulsions Breaking Global Monopoly

Certified for Global Markets, the Domestic MCT Solution Addresses Pharma Supply Chain Gaps 【Guangzhou, China】– 2026 – Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., a leading provider o

05
/
2026
08

Are Chinese EP Grade Injectable Soybean Oil Providers Reliable 2026 Expert Guide

This professional guide is crafted by senior quality and compliance experts with 28 years of industry experience from Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., a global leading pro

10
/
2026
08

Baiyunshan Hanfang makes its debut at CPHI China 2026, joining you to discuss the new future of API internationalization.

From June 16 to 18, the 24th CPHI China 2026 concluded successfully at the Shanghai New International Expo Center. This year’s event was themed “Pooling Strength for Collaborative Innovation, Smartly Pioneering the Future of Pharmaceuticals,” with an exhibition area exceeding 240,000 square meters. It brought together more than 3,600 exhibitors from around the world and over 110,000 professional visitors, focusing on cutting-edge technologies in the pharmaceutical industry and global market trends, while establishing a hub platform for exchange and cooperation across the entire industrial chain. Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., a subsidiary of Guangyao Group—a Fortune Global 500 company—showcased its core products, engaged in face-to-face discussions with industry partners, explored new opportunities for collaboration, and jointly mapped out a new vision for the industry.

04
/
2026
08

Egg Yolk Lecithin for Fat Emulsion 2026 Guide to Chinese Suppliers Industry Standards

This professional guide is crafted by Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., a global leading provider of high-end pharmaceutical lipid excipients with over 25 years of industry

03
/
2026
08

Who Are the Suppliers of Medicinal Injectable Soybean Oil in China 2026 Complete Guide

This professional guide is crafted by Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., a global leading provider of high-end medicinal lipid excipients and APIs in the pharmaceutical manu

01
/
2026
08

2026 China Injectable Soybean Oil Manufacturers for DrugLoaded Fat Emulsions Complete Guide

Guangzhou, China – 2026 – This guide is developed by the research team of Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., a leading high-end pharmaceutical lipid excipient provider with

30
/
2026
07

What Are MCT Triglycerides 2026 Complete Guide Expert Insights

This professional guide is crafted by senior R&D experts from Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., a global leading provider of high-end pharmaceutical lipid excipients and he

29
/
2026
07

New findings from LNP research! Phospholipids are not just “auxiliary lipids”; they are also the “soulful helmsman” of organ-targeted delivery.

Currently, lipid nanoparticles (LNPs) are among the most clinically advanced drug delivery systems in the field of nucleic acid therapeutics, providing critical support for mRNA therapies through mechanisms such as protecting nucleic acids and enhancing cellular uptake. Traditional LNPs consist of four components: ionizable lipids, PEGylated lipids, cholesterol, and auxiliary lipids (phospholipids). For a long time, researchers have regarded phospholipids as structural auxiliary components of LNPs, responsible for mediating LNP self-assembly and maintaining membrane stability. However, a recent study published in Biomaterials, a top-tier journal in the biomaterials field [1], has found that phospholipids play a crucial role in the membrane fusion, in vivo escape, and transfection efficiency of selectively targeted lipid nanoparticles (SORT LNPs). This research demonstrates that the functional role of phospholipids in LNPs has gone beyond their traditional positioning as “auxiliary lipi